Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Calcium and vitamin D

This article was originally published in The Tan Sheet

Executive Summary

Vitamin D serum levels and calcium supplementation "appear to act largely together," a study in the Dec. 3 Journal of the National Cancer Institute finds. Maria Grau, MD, Dartmouth Medical School, Lebanon, N.H., et al. analyzed data from a previous trial on calcium for prevention of recurrent colorectal adenoma (1"The Tan Sheet" Jan. 18, 1999, p. 17). Vitamin D status "strongly modified the effect of calcium supplementation on adenoma recurrence," the authors report, adding that further study is needed on both the mechanism of interaction and "to clarify the amount of intake of each nutrient required for optimum protective effects"...

Vitamin D serum levels and calcium supplementation "appear to act largely together," a study in the Dec. 3 Journal of the National Cancer Institute finds. Maria Grau, MD, Dartmouth Medical School, Lebanon, N.H., et al. analyzed data from a previous trial on calcium for prevention of recurrent colorectal adenoma (1 (Also see "Calcium Linked To "Moderate" Reduction In Colorectal Adenoma Risk" - Pink Sheet, 18 Jan, 1999.), p. 17). Vitamin D status "strongly modified the effect of calcium supplementation on adenoma recurrence," the authors report, adding that further study is needed on both the mechanism of interaction and "to clarify the amount of intake of each nutrient required for optimum protective effects"....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096259

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel